Opko Health Stock News

MetLife Investment Management LLC cut its position in shares of OPKO Health, Inc. (NASDAQ:OPK) by 20.7% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 120,352 shares of the biotechnology company’s stock after selling 31,506 shares during the period. MetLife Investment Management LLC’s holdings in OPKO Health were worth $487,000 at the end of the […]

Are these high volume penny stocks on your watchlist right now? The post 3 Top Penny Stocks With High Volume Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.

Are these high volume penny stocks on your watchlist right now? The post 3 Top Penny Stocks With High Volume Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.

Beacon Pointe Advisors LLC purchased a new stake in shares of OPKO Health, Inc. (NASDAQ:OPK) in the second quarter, HoldingsChannel.com reports. The institutional investor purchased 12,600 shares of the biotechnology companys stock, valued at approximately $51,000. A number of other hedge funds and other institutional investors have also modified their holdings of OPK. D. E. []

Charles Schwab Investment Management Inc. grew its stake in shares of OPKO Health, Inc. (NASDAQ:OPK) by 0.7% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 3,641,656 shares of the biotechnology companys stock after acquiring an additional 26,314 shares during the quarter. Charles Schwab Investment []

OPKO Health's (OPK) third-quarter results benefit from strength in its Pharmaceuticals segment, backed by robust RAYALDEE sales.

OPKO Health Inc (NASDAQ: OPK) reported Q3 revenues were down 10% Y/Y to $385.8 million, beating the consensus of $302.27 million. Revenue from diagnostic services decreased to $340.1 million from $3

OPKO Health's (OPK) CEO Phillip Frost on Q3 2021 Results - Earnings Call Transcript

OPKO Health (OPK) delivered earnings and revenue surprises of 500.00% and 26.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

MIAMI, Oct. 25, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended September 30, 2021, as well as discuss financial gui

On Monday, Opko Health Inc. (NASDAQ:OPK) shares edged slightly higher after Jefferies and Piper Sandler analysts issued upbeat statements following Friday's decline. The OPK stock price slipped more t

The FDA extends the PDUFA action date for OPKO (OPK)/Pfizer's BLA for somatrogon to treat pediatric patients with growth hormone deficiency. The review period has been further extended by three months

NEW YORK and MIAMI, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has extended the revi

GAITHERSBURG, Md., Sept. 21, 2021 /PRNewswire/ -- GeneDx, Inc., a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today

I think OPKO Health is significantly undervalued, specifically Rayaldee, and OPK could be a defensive stock even in a risk off repositioning in global markets.